The Eaton Vance Fund sells Novartis, Pfizer

The


Eaton Vance Worldwide Health Sciences Fund
(Trades, Portfolio) sold shares of the following stocks during the first quarter of 2021, which ended on March 31.

Novartis

The guru’s Novartis AG (NVS) position was reduced by 45.61%, impacting the portfolio by -1.91%.

03bb01e9359a97af09f23e6aa3a42ba8.png

The company, which develops and manufactures healthcare products, has a market cap of $193.34 billion and an enterprise value of $218.55 billion.

GuruFocus gives the company a profitability and growth rating of 7 out of 10. The return on equity of 14.71% and return on assets of 6.37% are outperforming 71% of companies in the drug manufacturers industry. Its financial strength is rated 5 out of 10 with a cash-debt ratio of 0.3.

The largest guru shareholder of the company is


PRIMECAP Management
(Trades, Portfolio) with 0.97% of outstanding shares, followed by Dodge & Cox with 0.96% and
Ken Fisher
(Trades, Portfolio) with 0.43%.

Pfizer

The guru curbed the position in Pfizer Inc. (PFE) by 36.52%, impacting the portfolio by -0.87%.

ca32cb43d494207c80b3f9d2e09ee3e4.png

The pharmaceutical firm has a market cap of $215.32 billion and an enterprise value of $241.61 billion.

GuruFocus gives the company a profitability and growth rating of 7 out of 10. The return on equity of 14.98% and return on assets of 5.69% are underperforming 69% of companies in the industry. Its financial strength is rated 5 out of 10. The cash-debt ratio of 0.32 is below the industry median of 1.

The largest guru shareholders of the company include


Vanguard Health Care Fund
(Trades, Portfolio) with 1.32% of outstanding shares,
Pioneer Investments
(Trades, Portfolio) with 0.18%,
Diamond Hill Capital
(Trades, Portfolio) with 0.17% and the
T Rowe Price Equity Income Fund
(Trades, Portfolio) with 0.08%.

Agilent Technologies

The firm trimmed its position in Agilent Technologies Inc. (A) by 42.66%. The trade had an impact of -0.77% on the portfolio.

0b49322f3e77958416be1d9997c818e6.png

The company has a market cap of $40.88 billion and an enterprise value of $ 42.05 billion.

GuruFocus gives the company a profitability and growth rating of 7 out of 10. The return on equity of 16.68% and return on assets of 8.47% are outperforming 74% of companies in the medical devices and instruments industry. Its financial strength is rated 6 out of 10 with a cash-debt ratio of 0.53.

The largest guru shareholder of the company is


Bill Ackman
(Trades, Portfolio) with 4.01% of outstanding shares, followed by
PRIMECAP Management
(Trades, Portfolio) with 1.04% and the
Vanguard Health Care Fund
(Trades, Portfolio) with 1%.

Abbott Laboratories

The guru curbed the position in Abbott Laboratories (ABT) by 15.37%, impacting the portfolio by -0.62%.

f208f3c329d8cef694a64235adbf69e2.png

The company, which manufactures medical devices as well as adult and pediatric nutritional products, has a market cap of $214.37 billion and an enterprise value of $227.09 billion.

GuruFocus gives the company a profitability and growth rating of 7 out of 10. The return on equity of 18.34% and return on assets of 8.29% are outperforming 78% of companies in the same industry. Its financial strength is rated 6 out of 10. The cash-debt ratio of 0.36 is below the industry median of 2.51.

The largest guru shareholders of the company include the


Vanguard Health Care Fund
(Trades, Portfolio) with 0.74% of outstanding shares, Fisher with 0.44%,
PRIMECAP Management
(Trades, Portfolio) with 0.36% and
Diamond Hill Capital
(Trades, Portfolio) with 0.33%.

Abiomed

The firm closed its position in Abiomed Inc. (ABMD), impacting the portfolio by -0.61%.

62a290b003e1e072222ad39da6661dbd.png

The company, which provides temporary mechanical circulatory support devices, has a market cap of $14.61 billion and an enterprise value of $14.12 billion.

GuruFocus gives the company a profitability and growth rating of 8 out of 10. The return on equity of 17.72% and return on assets of 15.62% are outperforming 83% of companies in the industry. Its financial strength is rated 9 out of 10 with no debt.

The largest guru shareholder of the company is BAILLIE GIFFORD & CO with 6.73% of outstanding shares, followed by


Frank Sands
(Trades, Portfolio) with 6.54%,
PRIMECAP Management
(Trades, Portfolio) with 4.53% and
Jim Simons
(Trades, Portfolio)’ Renaissance Technologies with 4.41%.

Disclosure: I do not own any stocks mentioned.

Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here.

Leave a Reply

Your email address will not be published. Required fields are marked *

scroll to top